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Ashdown’s medium, Burkholderia pseudomallei selective agar (BPSA), and a commercial Burkholderia cepacia
medium were compared for their abilities to grow B. pseudomallei from 155 clinical specimens that proved
positive for this organism. The sensitivity of each was equivalent; the selectivity of BPSA was lower than that
of Ashdown’s or B. cepacia medium.
Burkholderia pseudomallei is a gram-negative soil saprophyte
and the cause of melioidosis, a disease that is endemic in
southeast Asia and northern Australia (4). Isolation of the
organism from any sample is diagnostic for melioidosis and
remains the “gold standard.” Specimens from nonsterile sites
may be the only specimen positive by culture, and the use of
selective agar is necessary to reduce the overgrowth and mask-
ing of B. pseudomallei by commensal flora. Ashdown’s agar is
the most common selective medium in use in countries where
the disease is endemic (1, 5). The presumptive identification of
colonies of B. pseudomallei can be made from their character-
istic purple color and dry and wrinkled appearance, which
becomes evident after 24 to 48 h of incubation.
A second medium, B. pseudomallei selective agar (BPSA),
which may enhance the growth of mucoid colonies compared
with that on Ashdown’s medium has recently been described
(3), but this has not been extensively evaluated for the detec-
tion of B. pseudomallei in clinical samples. Neither medium is
commercially available, and so they are not rapidly accessible
to laboratories in areas of nonendemicity during the investiga-
tion of patients returning from abroad with suspected melioid-
osis or for use in the event of a suspected bioterrorist release
of B. pseudomallei. Burkholderia cepacia medium, an agar most
commonly used to identify B. cepacia complex from the spu-
tum of individuals with cystic fibrosis, is widely available; but its
ability to isolate B. pseudomallei in clinical samples has not
been reported. The aim of this prospective study was to com-
pare these three media in a clinical diagnostic setting in north-
east Thailand and to determine their relative sensitivities and
selectivities.
Ashdown’s agar was prepared as originally described (1), B.
cepacia medium was prepared according to the manufacturer’s
recommendations (Mast Diagnostics, Merseyside, United
Kingdom), and BPSA was prepared as described by Howard
and Inglis (3). Patients were recruited prospectively between
July and November 2003 by a study team at Sappasithiprasong
Hospital, Ubon Ratchathani, northeast Thailand. Patients with
suspected melioidosis were actively sought during twice-daily
ward rounds of the medical and intensive care wards. Blood
and throat swab specimens for microbiological culture were
taken from all patients; and urine, pus, and respiratory secre-
tions were collected where available.
Specimens of urine, pus, respiratory secretions, and throat
and wound swabs were plated directly onto the three media
(BPSA, Ashdown’s, and B. cepacia medium) in a random order
(as defined by a random-number table) to minimize any sys-
tematic bias. Quantitative bacterial counts were performed by
adding an equal volume of water to lyse pus cells and then
serially diluting and spread plating 10 l onto each of the three
media. Samples from sterile sites (pus and aspirates) were also
cultured using tryptic soy broth (TSB), and samples from non-
sterile sites (respiratory secretions and throat and wound
swabs) were cultured using selective enrichment broth (TSB
containing 4% glycerol, 0.05% crystal violet, and colistin at a
final concentration of 50 mg/liter). The broths were subcul-
tured undiluted and after serial dilution onto the three media
after 48 h incubation in air at 37°C. Blood cultures were per-
formed using BacT/ALERT FA bottles (BioMe´rieux); these
were incubated in air at 37°C and were subcultured undiluted
onto the three media after 24 h, 48 h, and 7 days and on
intervening days if the bottles became cloudy or the bottle
indicator changed color. Blood cultures were examined by se-
rial dilution when the bottle was cloudy or was considered
positive for other reasons. All agar plates were incubated in air
at 37°C and were examined after 24, 48, and 72 h. The growth
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of B. pseudomallei and other organisms was recorded. The
identification of B. pseudomallei was made on the basis of
Gram stain, resistance to gentamicin and colistin, the inability
to assimilate arabinose, and positivity by indirect immunoflu-
orescence (7) and latex agglutination (6). A test with the API
20NE system was performed if any doubt remained; this has
been reported to have a high degree of accuracy in our setting
(2). Other microorganisms were identified by standard labora-
tory methodologies. Statistical analysis was performed by using
the statistical program Intercooled STATA, version 8.0
(STATA, College Station, Tex.).
Cultures of 155 clinical specimens from 86 patients yielded
B. pseudomallei on at least one selective medium (range, 1 to 4
positive samples per patient). Positive cultures were from the
following specimen types: 56 blood samples (36%), 31 respi-
ratory secretions (19%), 17 pus samples (11%), 25 throat
swabs (16%), 12 wound swabs (8%), 13 urine specimens (8%),
and 1 pleural fluid specimen (1%). Of these, 63 specimens
(41%) were positive on primary culture (i.e., B. pseudomallei
was grown on agar plated directly with the sample), while the
remaining 92 specimens (59%) were positive only with samples
from enrichment broth.
On qualitative comparison, the B. pseudomallei colonies
grew on all three media, with two exceptions. In one case, a
single colony of B. pseudomallei grew on BPSA but not on
Ashdown’s or B. cepacia medium; in another comparison, a
single colony grew on Ashdown’s medium but not BPSA or B.
cepacia medium. This may reflect a stochastic phenomenon
related to the low bacterial concentrations in the sample. A
total of 115 samples examined by quantitative bacterial count
were positive for B. pseudomallei. Colony counts on B. cepacia
medium were significantly higher than those on either Ash-
down’s medium or BPSA on all 3 days (Table 1). There was no
difference in colony counts between Ashdown’s medium and
BPSA.
After 18 h of incubation, there was obvious growth of B.
pseudomallei on BPSA and B. cepacia medium, but only pin-
point growth was present on Ashdown’s medium. At 24 h,
colonies growing on B. cepacia medium were between 1 and 1.5
mm in diameter, on BPSA they were approximately 1 mm, and
on Ashdown’s medium they were approximately 0.5 mm. By
48 h, B. pseudomallei colonies were larger on BPSA and B.
cepacia medium but were obvious on all three media. The
colonial morphology of B. pseudomallei was often mucoid on
BPSA, but these strains were also observed to grow on Ash-
down’s and B. cepacia media. A mixture culture of randomly
selected clinical isolates of B. pseudomallei and B. cepacia was
spread plated onto B. cepacia medium; it was not possible to
distinguish reliably between these two species based on colony
morphology after 2, 3, or 4 days of incubation in air at 37°C
(data not shown).
In total, 524 Ashdown’s and B. cepacia medium plates and
526 BPSA plates were inoculated with clinical samples. There
was no difference in selectivity (based on ability to prevent the
growth of other species), between Ashdown’s medium and B.
cepacia medium (Fisher’s exact test, P  0.23). BPSA was
significantly less selective than either Ashdown’s medium or B.
cepacia medium (Fisher’s exact test, P  0.0001 in both cases)
(Table 2). Organisms that were difficult to distinguish from B.
pseudomallei (Klebsiella and Pseudomonas spp.) were identified
to species level. The colony morphology of the majority of
organisms that grew on one or more media was clearly differ-
ent from that of B. pseudomallei, and these isolates were not
further identified.
We propose that Ashdown’s medium should remain the
standard selective medium for clinical specimens in regions
TABLE 1. Quantitative median values of B. pseudomallei colony counts
Medium
Quantitative median count (106 CFU/ml [IQR])a
Media compared
Statistical comparison P value
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3
BPSA 227 (37–390) 235 (57–440) 280 (38–670) BPSA vs Ashdown’s medium 0.82 0.05 0.21
Ashdown’s medium 205 (41–400) 231 (50–450) 289 (42–510) B. cepacia medium vs
Ashdown’s medium
0.0001 0.0001 0.001
B. cepacia medium 280 (60–620) 281 (66–615) 300 (45–640) BPSA vs B. cepacia medium 0.0001 0.0001 0.0003
a IQR, interquartile range. All statistical comparisons were performed by the Wilcoxon signed-rank test.
TABLE 2. Other bacterial species and organisms growing on solid media
Organism
No. (%) of isolates recovered on the following medium (total no. of plates):
BPSA
(n  526)
Ashdown’s medium
(n  524)
B. cepacia medium
(n  524)
Staphylococcus spp. 13 (2) 4 (1) 4 (1)
Enterococcus spp. 5 (1) 0 (0) 0 (0)
Klebsiella species 4 (1) 5 (1) 8 (2)
Pseudomonas aeruginosa 4 (1) 5 (1) 4 (1)
Other gram-negative bacilli, not further identified 7 (2) 0 (0) 0 (0)
Fungi 14 (3) 0 (0) 8 (2)
Mixed organismsa 20 (4) 7 (1) 13 (2)
Colonies, not further identified 96 (18) 52 (10) 51 (10)
Total 163 (31) 73 (14) 88 (17)
a Two or more species in addition to B. pseudomallei.
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where melioidosis is endemic. B. cepacia medium represents a
widely available, acceptable alternative in areas of nonende-
micity for the isolation of B. pseudomallei from patients with
suspected melioidosis. This medium also supports the growth
of B. mallei and would be suitable for screening during a
deliberate-release event involving B. pseudomallei and/or B.
mallei.
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